Alzamend Neuro

At the company’s current cash level, Alzamend requires new financing or a partner before next major clinical milestones if it is to continue advancing AL001/ALZN002; absent external funding the programs will be delayed or stopped. If true, ownership is binary on clinical/partnering catalysts; if false (company raises material non-dilutive/partner capital) the equity can appreciate without severe dilution.

Alzamend’s operating cash flow has been persistently negative at multi‑million dollar annual rates and will continue to deplete cash unless spending is cut or external funding arrives. Persistent multi‑million dollar burn shortens runway, forces financing or partnerships, and increases dilution risk; a sustainable reduction would validate management’s ability to conserve capital while advancing trials.

The company’s equity/base capital has swung materially year‑to‑year, reflecting past financings and implying future capital raises will likely be dilutive versus delivering non‑dilutive partner funding. If growth is funded by equity, current holders will be diluted; if funded by non‑dilutive deals, value per share can rise without dilution.

Operating losses have narrowed from earlier peaks, suggesting some cost control, but remain substantial and not self‑funding; this buys time but does not eliminate the need for external capital to reach late‑stage value inflections. If losses continue to shrink and management can stretch runway to a de‑risking readout, dilution pressure falls; if losses widen (e.g., larger trial starts), runway shortens.